(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 22 October 2015 - Actelion Ltd (SIX: ATLN) today announced that further key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®) will be shared through a poster presentation at the American College of Chest Physicians' CHEST Congress in Montréal, Canada. The poster, titled 'Individualized dosing of selexipag based on tolerability in the GRIPHON study shows consistent efficacy and safety in patients with pulmonary arterial hypertension' will be presented by Dr Richard Channick from Massachusetts General Hospital, Boston, USA, at 13.30...
↧